A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases

ClinicoEconomics and Outcomes Research

Volumn 6, Issue , 2014, Pages 431-443

  Odes, Shmuel ^a   Greenberg, Dan ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Biologic therapy; Cost effectiveness; Crohn s disease; Ulcerative colitis

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; CYCLOSPORIN; ETROLIZUMAB; GOLIMUMAB; IMMUNOMODULATING AGENT; INFLIXIMAB; NATALIZUMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; USTEKINUMAB; VEDOLIZUMAB;

COST CONTROL; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DEVELOPING COUNTRY; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECONOMIC EVALUATION; HEART FAILURE; HUMAN; INFECTION; INFLAMMATORY BOWEL DISEASE; INJECTION SITE REACTION; LEUKOENCEPHALOPATHY; LOADING DRUG DOSE; LYMPHOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; ULCERATIVE COLITIS;

EID: 84908248395     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S39212     Document Type: Review

References (75)

1. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5-36.
2. Burisch J, Pedersen N, Čuković-Čavka S, et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut. 2014;63(4):588-597.
3. Borg S, Persson U, Jess T, et al. A maximum likelihood estimator of a Markov model for disease activity in Crohn’s disease and ulcerative colitis for annually aggregated partial observations. Med Decis Making. 2010;30(1):132-142.
4. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol. 1995;30(7):699-706.
5. Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol. 1997;32(11): 1134-1139.
6. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60(5):571-607.
7. Blonski W, Buchner AM, Lichtenstein GR. Inflammatory bowel disease therapy: current state-of-the-art. Curr Opin Gastroenterol. 2011;27(4):346-357.
8. Chevaux J-B, Vavricka SR, Rogler G, Lakatos PL, Schoepfer A, Peyrin-Biroulet L. Mucosal healing with anti-TNF antibodies. Digestion. 2012;86(Suppl 1):16-22.
9. Odes S. How expensive is inflammatory bowel disease? A critical analysis. World J Gastroenterol. 2005;14(43):6641-6647.
10. Bosani A, Ardizonne S, Porro GB. Biologic targeting in the treatment of inflammatory bowel diseases. Biologics. 2009;3:77-97.
11. Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):644-659.
12. Kawalec P, Mikrut A, Wiśniewska N, Pilc A. Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn’s disease: systematic review and meta-analysis. Arch Med Sci. 2013;9:765-779.
13. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-1 trial. Gastroenterology. 2006;130(2):323-333.
14. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalumumab induction therapy for Crohn’s disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12):829-838.
15. Sandborn WJ, Schreiber S, Feagan BG, et al. Certolizumab pegol for active Crohn’s disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2011;9(8):670-678.
16. Winter TA, Wright J, Ghosh S, et al. Intravenous CDP870, a PEGylated Fab’ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn’s disease; an exploratory study. Aliment Pharmacol Ther. 2004;20(11-12):1337-1346.
17. Schreiber S, Lawrance IC, Thomson O, et al. Randomized clinical trial: certolimumab pegol for fistulas in Crohn’s disease: sub-group results from a placebo-controlled study. Aliment Pharmacol Ther. 2011;33(2):185-193.
18. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010; 362(15):1383-1395.
19. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s disease cA2 Study Group. N Engl J Med. 1997;337(15):1029-1035.
20. D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with new diagnosed Crohn’s disease: an open randomized trial. Lancet. 2008;371(9613): 660-667.
21. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE trial. Gastroenterology. 2007;136(5):1672-1683.
22. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintemence therapy for Crohn’s disease. N Engl J Med. 2005;353(18): 1912-1925.
23. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353(23):2462-2476.
24. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6): 780-787.
25. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(5):257-265.
26. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85-95.
27. Stidham RW, Lee TCH, Higgins PDR, et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther. 2014;39(12):1399-1362.
28. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc. 2006;63(3):433-442.
29. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm Bowel Dis. 2009;15(9):1295-1301.
30. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009;104(3):760-767.
31. Ricart E, Ordas I, Panes J. Anti-TNF antibody therapy in Crohn’s disease: the risk of a switch. Gut. 2012;61(2):169-170.
32. Allez M, Vermeire S, Mozziconacci N, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther. 2010;31(1):92-101.
33. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392-400.
34. Lv R, Qiao W, Wu Z, et al. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis. PLos One. 2014;9(1):e86692.
35. Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomized controlled trial. Lancet. 2012;380(9857):1909-1915.
36. Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014;39(7):660-671.
37. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367(16):1519-1528.
38. Lobatón T, Vermeire S, Van Assche G, Rutgeerts P. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39(6):579-594.
39. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711-721.
40. Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis. 2012;18(8):1470-1479.
41. Vermeire S, O’Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomized, controlled, phase 2 trial. Lancet. 2014;384(9940):309-318.
42. Juillerat P, Wasan SK, Fowler SA, et al. Efficacy and safety of natalizumab in Crohn’s disease patients treated at 6 Boston academic hospitals. Inflamm Bowel Dis. 2013;19(11):2457-2463.
43. Sakuraba A, Keyashian K, Correia C, et al. Natalizumab in Crohn’s disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013;19(3):621-626.
44. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117(1):49-57.
45. Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol. 1992;14(4):318-327.
46. Feagan BG, Vreeland MG, Larson LR, Bala MV. Annual cost of care for Crohn’s disease: a payor perspective. Am L Gastroenterol. 2000;95(8):1955-1960.
47. Cohen RD, Larson LR, Roth JM, Becker RV, Mummert LL. The cost of hospitalization in Crohn’s disease. Am J Gastroenterol. 2000;95(2): 524-530.
48. Bernstein CN, Papineau N, Zajaczkowski J, Rawsthorne P, Okrusko G, Blanchard JF. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol. 2000;95(3):677-683.
49. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004;53(10):1471-1478.
50. Ebinger M, Leidl R, Thomas S, et al. Cost of outpatient care in patients with inflammatory bowel disease in a German university hospital. J Gastroenterol Hepatol. 2004;19(2):192-199.
51. Odes S, Vardi h, Friger m, et al. Cost-analysis and cost-determinants in a European inflammatory bowel disease inception cohort with 10 years follow-up evaluation. Gastroenterology. 2006;131(3): 719-728.
52. Bernstein CN, Longobardi T, Finlayson G, Blanchard JF. Direct medical costs of managing IBD patients: a population-based study. Inflamm Bowel Dis. 2012;18(8):1498-1508.
53. Van der Walk ME, Mangen MJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalization and surgery towards anti-TNF therapy: results from the COIN study. Gut. 2014;63(1):72-79.
54. Benedini V, Caporaso N, Corazza GR, et al. Burden of Crohn’s disease: economics and quality of life aspects in Italy. Clinicoecon Outcomes Res. 2012;4:209-218.
55. Saro C, de la Coba C, Casad MA, Morales JM, Otero B. Resource use in patients with Crohn’s disease treated with infliximab. Aliment Pharmacol Ther. 2007;26(10):1313-1323.
56. Loomes DE, Teshima C, Jacobs P, Fedorak RN. Health care resource use and cost in Crohn’s disease before and after infliximab. Can J Gastroenterol. 2011;25(9):497-502.
57. Cost-Effectiveness Analysis Registry [homepage on the Internet]. Available from: https://research.tufts-nemc.org/cear. Boston, MA: Tufts Medical Center. Accessed August 29, 2014.
58. Saito S, Shimizu U, Nan Z, et al. Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn’s disease: a cost-effectiveness analysis. J Crohn’s Colitis. 2013;7(2): 167-174.
59. Marchetti M, Liberato NL, Di Sabatino A, Corazza GR. Cost-effectiveness of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn’s disease. Eur J Health Econ. 2013;14(6):853-861.
60. Tang DH, Armstrong EP, Lee JK. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn’s disease. Pharmacotherapy. 2012;32(6):515-526.
61. Blackhouse G, Assasi N, Xie F, et al. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn’s disease. J Crohn’s Colitis. 2012;6(1):77-85.
62. Ananthankrishnan AN, Hur C, Korzenik JR. Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn’s disease: results of a decision analysis. Dig Dis Sci. 2012;57(2): 472-480.
63. Yu AP, Johnson S, Wang ST, et al. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn’s disease. Pharmacoeconomics. 2009;27(7):609-621.
64. Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther. 2009;30(3):265-274.
65. Loftus EV Jr, Johnson SJ, Yu AP, Wu EQ, Chao J, Mulani PM. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn’s disease. Eur J Gastroenterol Hepatol. 2009;21(11):1302-1309.
66. Lindsay J, Punekar Y, Morris J, Chung-Faye G. Health-economic analysis: Cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease-modelling outcomes in active luminal and fistulising disease in adults. Aliment Pharmacol Ther. 2008;28(1):76-87.
67. Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose-escalation vs initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2007;26(11-12): 1509-1520.
68. Punekar YS, Hawkins N. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis. Eur J Health Econ. 2010;11(1):67-76.
69. Xie F, Blackhouse G, Assasi N, Gaebel K, Robertson D, Goeree R. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost Eff Resour Alloc. 2009;11:7:20.
70. Tsai HH, Punekar YS, Morris J, Fortun P. A model of the long-term cost-effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2008; 28(10):1230-1239.
71. Tang DH, Harrington AR, Lee JK, Lin M, Armstrong EP. A systematic review of economic studies on biological agents used to treat Crohn’s disease. Inflamm Bowel Dis. 2013;19(12):2673-2694.
72. Rogler G, Bernstein CN, Ajit S, et al. Role of biological therapy for inflammatory bowel disease developing countries. Gut. 2012;61(6): 706-712.
73. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. February 16, 2011;(2):CD008794.
74. Singh JA, Kumar N, Loftus EV Jr, Kane SV. Neurological complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics. Inflamm Bowel Dis. 2013;19(4):864-872.
75. Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA) patient survey. J Crohn’s Colitis. 2007;1:10-20.